Clinical Trials · NCT07244003
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
- Phase
- Phase 4
- Recruitment status
- Recruiting
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Enrollment
- 430
- Start date
- Mar 2025
- Locations
- 1 site, China
- Primary endpoint
- The change of HbA1c compared to the baseline